News | September 03, 2009

First Swedish Patients Receive MitraClip Therapy

September 3, 2009 – Percutaneous cardiac valve maker Evalve Inc. announced treatment this week of the first group of patients with the MitraClip system at the Karolinska University Hospital in Solna, Stockholm, Sweden.

The MitraClip system is the only medical device commercially available in the European Union that provides a nonsurgical mitral valve repair option for patients suffering from the effects of functional and degenerative mitral regurgitation (MR).

MR is the most common type of heart valve insufficiency in Europe and the United States, affecting millions of people worldwide. Significant MR affects more than eight million people in the U.S. and Europe, the majority of which have FMR. There are more than 600,000 new diagnoses of significant MR each year in Europe and the U.S.; however, only 20 percent of these patients undergo surgery each year. Many higher risk surgical patients and non-surgical patients continue to be affected by the chronic volume overload caused by MR, which requires the heart to work harder, and may ultimately lead to heart failure.

The first patients in Sweden were successfully treated by a team led by cardio-thoracic surgeon Anders Jonsson, M.D., Ph.D., assisted by interventional cardiologist Magnus Settergren, M.D., Ph.D. Echocardiography was performed by cardiac anesthetist Jan Hultman, M.D., Ph.D. and clinical cardiologist Reidar Winter, M.D., Ph.D.

"The MitraClip technology has added a new dimension to the treatment of mitral regurgitation. In my initial experience with our first three patients, I was very pleased to see the good result achieved with a single clip in each of our patients. Any less invasive approach for heart valve procedures is worthwhile to consider, especially if the long term results are compatible with the techniques requiring an open thorax. I am looking forward to treat more patients to further evaluate this approach," said Dr. Hultman, director of the clinic in cardiothoracic surgery and anesthesia. "It is very satisfactory for us as a unit to be able to offer this technology to some of our patients. The MitraClip is a device that hopefully will enable us to design the optimal treatment for all different types of patients with MR including high risk and inoperable candidates," added Dr. Jonsson, who led the team.

Evalve initiated commercial sales of the MitraClip system in Europe under the CE mark in late 2008. The company is employing a direct sales strategy and is taking a disciplined and measured approach to the initial commercial roll out. Evalve has worked closely with hospitals to deliver high quality training programs in preparation for the first series of implants and offers ongoing support. The MitraClip device is currently being implanted in six Western European countries, including Germany, Italy, the United Kingdom, the Netherlands, Switzerland and now Sweden.

"We are very pleased with the successful initial use of the MitraClip device in Sweden at this outstanding cardiac center," said Ferolyn Powell, president and chief executive officer of Evalve. "It is noteworthy that the MitraClip therapy can be delivered to patients by both interventional cardiologists and cardiothoracic surgeons in close collaboration with their colleagues in echocardiology. The centers offering the MitraClip therapy in Europe are pioneering a new field and era in the medical care for patients who suffer from mitral regurgitation, especially for those who, until now, had very limited therapeutic options."

For more information: www.evalveinc.com, www.thefoundry.com

Related Content

Abbott Receives FDA Approval for Third-Generation MitraClip Device
Technology | Heart Valve Technology | July 18, 2018
July 18, 2018 — Abbott announced it received approval from the U.S.
Videos | Heart Valve Technology | July 18, 2018
Jonathon Leipsic, M.D., FSCCT, professor of radiology and cardiology at the University of British Columbia, Vancouver
Videos | Heart Valve Technology | July 10, 2018
Ori Ben-Yehuda, M.D., executive director of the Cardiovascular Research Foundation Clinical Trial Center, discusses t
Videos | Heart Valve Technology | July 05, 2018
Rebecca Hahn, M.D., professor of medicine and director of interventional echocardiography, Columbia University Medica
Henry Ford Hospital First in Michigan to Perform Cardioband Mitral Valve Procedure

An angiography image showing the catheter-based implantation of the Cardioband annuloplasty ring using corkscrew shaped anchors.

News | Heart Valve Technology | June 13, 2018
Henry Ford Hospital is one of 17 U.S. trial sites using a catheter-based procedure approved in Europe to repair a leaky...
Abbott Portico transcatheter aortic valve replacement (TAVR) performed well PORTICO I real-world study. #EuroPCR
News | Heart Valve Technology | June 01, 2018
June 1, 2018 –  Use of the Abbott Portico transcatheter aortic valve replacement (TAVR) therapy was associated with e
Tendyne Transcatheter Mitral Valve Replacement Device Demonstrates Positive 30-Day Outcomes
News | Heart Valve Technology | May 25, 2018
Abbott announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter...
A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital.

A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital. 

Feature | Heart Valve Technology | May 14, 2018
May 14, 2018 – A new study finds patients who stay in the hospital for more than 72 hours when undergoing trans-femor
The use of 3-D printed hearts from patients' pre-TAVR planning CT scans have improved outcomes of procedures at the University of Minnesota. Clearly identifying where calcium is located on the valves prior to TAVR device implantation has helped reduce the incidence of paravalvular leak.  #SCAI, #SCAI2018

The use of 3-D printed hearts from patients' pre-TAVR planning CT scans have improved outcomes of procedures at the University of Minnesota. Clearly identifying where calcium is located on the valves prior to TAVR device implantation has helped reduce the incidence of paravalvular leak.

News | Heart Valve Technology | May 14, 2018
May 14, 2018 – A new study examines the effectiveness of 3-D printing technology and computer modeling to predict par
First-Ever Risk Tool Helps Predict TAVR Readmission Rates in 2018 SCAI late-breaking study. #SCAI, #SCAI2018
News | Heart Valve Technology | May 11, 2018
A new study looked at the effectiveness of a novel risk tool to predict 30-day readmission rates in patients undergoing...
Overlay Init